279 related articles for article (PubMed ID: 23635774)
1. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
Pozo N; Zahonero C; Fernández P; Liñares JM; Ayuso A; Hagiwara M; Pérez A; Ricoy JR; Hernández-Laín A; Sepúlveda JM; Sánchez-Gómez P
J Clin Invest; 2013 Jun; 123(6):2475-87. PubMed ID: 23635774
[TBL] [Abstract][Full Text] [Related]
2. DYRK1A activates NFATC1 to increase glioblastoma migration.
Liu H; Sun Q; Chen S; Chen L; Jia W; Zhao J; Sun X
Cancer Med; 2021 Sep; 10(18):6416-6427. PubMed ID: 34309232
[TBL] [Abstract][Full Text] [Related]
3. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
5. DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma.
Martin CE; Nguyen A; Kang MK; Kim RH; Park NH; Shin KH
Exp Cell Res; 2021 Aug; 405(1):112656. PubMed ID: 34033760
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
Guo G; Gong K; Puliyappadamba VT; Panchani N; Pan E; Mukherjee B; Damanwalla Z; Bharia S; Hatanpaa KJ; Gerber DE; Mickey BE; Patel TR; Sarkaria JN; Zhao D; Burma S; Habib AA
Neuro Oncol; 2019 Dec; 21(12):1529-1539. PubMed ID: 31363754
[TBL] [Abstract][Full Text] [Related]
8. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence.
Xu X; Liu Q; Zhang C; Ren S; Xu L; Zhao Z; Dou H; Li P; Zhang X; Gong Y; Shao C
Cell Death Dis; 2019 Mar; 10(4):282. PubMed ID: 30910997
[TBL] [Abstract][Full Text] [Related]
10. AshwaMAX and Withaferin A inhibits gliomas in cellular and murine orthotopic models.
Chang E; Pohling C; Natarajan A; Witney TH; Kaur J; Xu L; Gowrishankar G; D'Souza AL; Murty S; Schick S; Chen L; Wu N; Khaw P; Mischel P; Abbasi T; Usmani S; Mallick P; Gambhir SS
J Neurooncol; 2016 Jan; 126(2):253-64. PubMed ID: 26650066
[TBL] [Abstract][Full Text] [Related]
11. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Akhavan D; Pourzia AL; Nourian AA; Williams KJ; Nathanson D; Babic I; Villa GR; Tanaka K; Nael A; Yang H; Dang J; Vinters HV; Yong WH; Flagg M; Tamanoi F; Sasayama T; James CD; Kornblum HI; Cloughesy TF; Cavenee WK; Bensinger SJ; Mischel PS
Cancer Discov; 2013 May; 3(5):534-47. PubMed ID: 23533263
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
13. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
15. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
[TBL] [Abstract][Full Text] [Related]
16. Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma.
Massey AJ; Benwell K; Burbridge M; Kotschy A; Walmsley DL
J Cell Mol Med; 2021 Nov; 25(22):10650-10662. PubMed ID: 34708541
[TBL] [Abstract][Full Text] [Related]
17. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
Adayev T; Wegiel J; Hwang YW
Arch Biochem Biophys; 2011 Mar; 507(2):212-8. PubMed ID: 21185805
[TBL] [Abstract][Full Text] [Related]
18. DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
Li YL; Ding K; Hu X; Wu LW; Zhou DM; Rao MJ; Lin NM; Zhang C
J Cell Mol Med; 2019 Nov; 23(11):7427-7437. PubMed ID: 31454149
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.
Zahonero C; Aguilera P; Ramírez-Castillejo C; Pajares M; Bolós MV; Cantero D; Perez-Nuñez A; Hernández-Laín A; Sánchez-Gómez P; Sepúlveda JM
Mol Cancer Ther; 2015 Jul; 14(7):1548-58. PubMed ID: 25939761
[TBL] [Abstract][Full Text] [Related]
20. DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells.
Chen B; McCuaig-Walton D; Tan S; Montgomery AP; Day BW; Kassiou M; Munoz L; Recasens A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
